



ACCESS
Immunoassay Systems

Instructions For Use

© 2024 Beckman Coulter, Inc. All rights reserved.

Access GI Monitor Cancer Antigen 19-9

REF 387687

FOR PROFESSIONAL USE ONLY

Rx Only

PRINCIPLE

WARNING

The concentration of CA 19-9 antigen in a given specimen determined with assays from different manufacturers can vary due to differences in assay methods and reagent specificity. The results reported by the laboratory to the physician must include the identity of the CA 19-9 antigen assay used. Values obtained with different assay methods cannot be used interchangeably. If, in the course of monitoring a patient, the assay method used for determining CA 19-9 antigen values is changed, additional sequential testing should be carried out to confirm baseline values.

Patients must possess the ability to express the Lewis blood group antigen or they will be unable to produce the CA 19-9 antigen even in the presence of proven malignancy. A patient with a positive genotype for the Lewis antigen may produce varying levels of CA 19-9 antigen. Phenotyping for the presence of the Lewis blood group antigen may be insufficient to detect true Lewis antigen negative individuals.

INTENDED USE

The Access GI Monitor assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of CA 19-9 antigen levels in human serum and plasma using the Access Immunoassay Systems. This device is indicated for use in the measurement of CA 19-9 antigen to aid in the management of pancreatic cancer patients. The test is useful as an aid in monitoring of disease status in those patients having confirmed pancreatic cancer whose serum CA 19-9 antigen levels exceed 10 U/mL, the cut-off value for individuals who are Lewis blood group antigen negative. Serial testing for CA 19-9 antigen concentrations should be used in conjunction with other clinical methods used for monitoring pancreatic cancer.

SUMMARY AND EXPLANATION

The CA 19-9 antigen, a Lewis blood group-related mucin, is a tumor-associated antigen synthesized by normal human pancreatic and biliary ductular cells, and gastric, colonic, endometrial and salivary epithelia.^{1,2} Typically, only a minimal amount of the CA 19-9 antigen is present in the blood of normal subjects or subjects with benign disorders. Most patients with carcinoma of the pancreas, however, have elevated levels of blood CA 19-9 antigen.²

Initially found in colorectal cancer patients, the CA 19-9 antigen has also been identified in patients with pancreatic, bile duct, hepatocellular, stomach, and esophageal cancers. Non-cancerous conditions that may elevate CA 19-9 antigen levels include cirrhosis, cholangitis, hepatitis, pancreatitis, and non-malignant gastrointestinal diseases.^{2,3,4,5,6}

Generally, the incidence rates of pancreatic carcinoma are highest in Western and industrialized countries, and lowest in underdeveloped regions of the world. The incidence of pancreatic cancer in Europe is on the rise, while the incidence rate in the US has remained constant over the last 25 years. Pancreatic cancer is the fourth leading cause of cancer mortality in the US.¹

CA 19-9 antigen levels may be used as an aid in monitoring the response to therapy for patients with pancreatic cancer. In pancreatic cancer patients, high levels of CA 19-9 antigen tend to be associated with more advanced disease. The presence of persistently rising CA 19-9 antigen levels may be correlated with disease progression. Persistently elevated CA 19-9 antigen levels may indicate poor response to therapy, whereas decreasing CA 19-9 antigen levels may indicate a positive therapeutic response.^{7,8}

The Access GI Monitor assay is not recommended as a screening tool. A value below the cutoff limit does not indicate the absence of pancreatic cancer. Other clinically acceptable tests and procedures should also be considered in the monitoring of pancreatic cancer and good patient management.

METHODOLOGY

The Access GI Monitor assay is a two-site immunoenzymatic (“sandwich”) assay. A sample is added to a reaction vessel along with paramagnetic particles coated with polyclonal goat anti-biotin antibody, mouse monoclonal-biotin conjugate, and a buffered protein solution. After incubation in a reaction vessel, separation in a magnetic field and washing remove materials not bound to the solid phase. A monoclonal-alkaline phosphatase conjugate is then added.

After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Then, the chemiluminescent substrate is added to the vessel and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of CA 19-9 antigen in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve.

SPECIMEN

SPECIMEN COLLECTION AND PREPARATION

1. Serum and plasma (heparin) are the recommended samples.
2. Observe the following recommendations for handling, processing, and storing blood samples:⁹
 - Collect all blood samples observing routine precautions for venipuncture.
 - Allow serum samples to clot completely before centrifugation.
 - Keep tubes stoppered at all times.
 - Physically separate serum or plasma from contact with cells as soon as possible.
 - Store samples tightly stoppered at room temperature (15 to 30°C) for no longer than eight hours.
 - If the assay will not be completed within eight hours, refrigerate the samples at 2 to 8°C.
 - If the assay will not be completed within 48 hours, or for shipment of samples, freeze at -20°C or colder.
 - Thaw samples only once.
3. Use the following guidelines when preparing specimens:
 - Ensure residual fibrin and cellular matter has been removed prior to analysis.
 - Follow blood collection tube manufacturer's recommendations for centrifugation.
4. Each laboratory should determine the acceptability of its own blood collection tubes and serum separation products. Variations in these products may exist between manufacturers and, at times, from lot-to-lot.
5. Avoid assaying lipemic and/or hemolyzed samples.

REAGENTS

PRODUCT INFORMATION

Access GI Monitor Reagent Pack

Cat. No. 387687: 100 determinations, 2 packs, 50 tests/pack

- Provided ready to use.
- Store upright and refrigerate at 2 to 10°C.
- Refrigerate at 2 to 10°C for a minimum of two hours before use on the instrument.
- Stable until the expiration date stated on the label when stored at 2 to 10°C.
- Stable at 2 to 10°C for 56 days after initial use.
- Signs of possible deterioration are a broken elastomeric layer on the pack or control values out of range.
- If the reagent pack is damaged (i.e., broken elastomer), discard the pack.
- All antisera are polyclonal unless otherwise indicated.


R1a:	Paramagnetic particles, coated with goat polyclonal anti-biotin antibody, bovine serum albumin, < 0.1% sodium azide and 0.1% ProClin* 300.
R1b:	Mouse monoclonal anti-CA 19-9 antigen-alkaline phosphatase (bovine) conjugate, bovine serum albumin, < 0.1% sodium azide and 0.1% ProClin 300.
R1c:	Mouse monoclonal anti-CA 19-9 antigen-biotin conjugate, bovine serum albumin, < 0.1% sodium azide and 0.1% ProClin 300.
R1d:	Buffered protein solution (bovine, goat, mouse), < 0.1% sodium azide, and 0.1% ProClin 300.

*ProClin is a trademark of LANXESS Corp.

WARNING AND PRECAUTIONS

- For *in vitro* diagnostic use.
- Patient samples and blood-derived products may be routinely processed with minimum risk using the procedure described. However, handle these products as potentially infectious according to universal precautions and good clinical laboratory practices, regardless of their origin, treatment, or prior certification. Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers in accordance with local regulations and guidelines.
- Human source material used in the preparation of the reagent has been tested and found negative or non-reactive for Hepatitis B, Hepatitis C (HCV), and Human Immunodeficiency Virus (HIV-1 and HIV-2). Because no known test method can offer complete assurance that infectious agents are absent, handle reagents and patient samples as if capable of transmitting infectious disease.¹⁰
- For hazards presented by the product refer to the following sections: REACTIVE INGREDIENTS and GHS HAZARD CLASSIFICATION.

REACTIVE INGREDIENTS

 CAUTION
<p>Sodium azide preservative may form explosive compounds in metal drain lines. See NIOSH Bulletin: Explosive Azide Hazard (8/16/76). To avoid the possible build-up of azide compounds, flush wastepipes with water after the disposal of undiluted reagent. Sodium azide disposal must be in accordance with appropriate local regulations.</p>

GHS HAZARD CLASSIFICATION

PMP (Compartment R1a)

WARNING



H317

May cause an allergic skin reaction.

H412

Harmful to aquatic life with long lasting effects.

P273

Avoid release to the environment.

P280

Wear protective gloves, protective clothing and eye/face protection.

P333+P313

If skin irritation or rash occurs: Get medical advice/attention.

P362+P364

Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

Conjugate (Compartment R1b)

WARNING



H317

May cause an allergic skin reaction.

H412

Harmful to aquatic life with long lasting effects.

P273

Avoid release to the environment.

P280

Wear protective gloves, protective clothing and eye/face protection.

P333+P313

If skin irritation or rash occurs: Get medical advice/attention.

P362+P364

Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

Conjugate (Compartment R1c)

WARNING



H317

May cause an allergic skin reaction.

H412

Harmful to aquatic life with long lasting effects.

P273

Avoid release to the environment.

P280

Wear protective gloves, protective clothing and eye/face protection.

P333+P313

If skin irritation or rash occurs: Get medical advice/attention.

P362+P364

Take off contaminated clothing and wash it before use.


reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

Blocking Agent (Compartment R1d) WARNING



H317	May cause an allergic skin reaction.
H412	Harmful to aquatic life with long lasting effects.
P273	Avoid release to the environment.
P280	Wear protective gloves, protective clothing and eye/face protection.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before use.

reaction mass of: 5-chloro-2-methyl-4-isothiazolin -3-one [EC# 247-500-7] and 2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1) < 0.05%

	Safety Data Sheet is available at beckmancoulter.com/techdocs
---	---

MATERIALS NEEDED BUT NOT SUPPLIED WITH REAGENT KIT

1. Access GI Monitor Calibrators
Provided at zero and approximately 30, 90, 300, 900 and 2,000 U/mL
Cat. No. 387688
2. Quality Control (QC) materials: commercial control material
3. Access Sample Diluent A
Vial Cat. No. 81908
Diluent Pack Cat. No. A79783 (For use with the UniCel DxI system onboard dilution feature.)
4. Access Substrate
Cat. No. 81906
5. Access Wash Buffer II, Cat. No. A16792
UniCel DxI Wash Buffer II, Cat. No. A16793

EQUIPMENT AND MATERIALS

R1 Access GI Monitor Reagent Packs

CALIBRATION

CALIBRATION INFORMATION

An active calibration curve is required for all tests. For the Access GI Monitor assay, calibration is required every 56 days. Refer to the appropriate system manuals and/or Help system for information on calibration theory, configuring calibrators, calibrator test request entry, and reviewing calibration data.

QUALITY CONTROL

Quality control materials simulate the characteristics of patient samples and are essential for monitoring the system performance of immunochemical assays. Because samples can be processed at any time in a “random access” format rather than a “batch” format, quality control materials should be included in each 24-hour time period.¹¹ Include commercially available quality control materials that cover at least two levels of analyte. More frequent use of controls or the use of additional controls is left to the discretion of the user based on good laboratory practices or laboratory accreditation requirements and applicable laws. Follow manufacturer's instructions for reconstitution and storage. Each laboratory should establish mean values and acceptable ranges to assure proper performance. Quality control results that do not fall within acceptable ranges may indicate invalid test results. Examine all test results generated since obtaining the last acceptable quality control test point for this analyte. Refer to the appropriate system manuals and/or Help system for information about reviewing quality control results.

TESTING PROCEDURE(S)

PROCEDURAL COMMENTS

1. Refer to the appropriate system manuals and/or Help system for a specific description of installation, start-up, principles of operation, system performance characteristics, operating instructions, calibration procedures, operational limitations and precautions, hazards, maintenance, and troubleshooting.
2. Mix contents of new (unpunctured) reagent packs by gently inverting pack several times before loading on the instrument. Do not invert open (punctured) packs.
3. Use ten (10) μL of sample for each determination in addition to the sample container and system dead volumes. Use fifty (50) μL of sample in addition to the sample container and system dead volumes for each determination run with the DxI system onboard dilution feature. Refer to the appropriate system manuals and/or Help system for the minimum sample volume required.
4. The system default unit of measure for sample results is U/mL.

PROCEDURE

Refer to the appropriate system manuals and/or Help system for information on managing samples, configuring tests, requesting tests, and reviewing test results.

RESULTS INTERPRETATION

Patient test results are determined automatically by the system software using a smoothing spline math model. The amount of analyte in the sample is determined from the measured light production by means of the stored calibration data. Patient test results can be reviewed using the appropriate screen. Refer to the appropriate system manuals and/or Help system for complete instructions on reviewing sample results.

REPORTING RESULTS

EXPECTED RESULTS

1. Each laboratory should establish its own reference ranges to assure proper representation of specific populations.

2. The distribution of Access GI Monitor results, presented below were determined from a total of 1,322 serum samples from apparently healthy males and females and from males and females with non-malignant and malignant conditions.

Subject Category	Number of Subjects	0-35 U/mL	35.1-70 U/mL	70.1-100 U/mL	> 100 U/mL
Apparently Healthy					
Females	150	141	8	1	0
Males	141	134	6	1	0
Malignant Conditions[†]					
Pancreas	40	10	2	5	23
Biliary/ Gallbladder	25	13	0	0	12
Breast	37	35	0	1	1
Gastrointestinal	142	102	21	0	19
Genitourinary	111	95	9	4	3
Liver	84	67	9	0	8
Lung	70	52	11	1	6
Non-Malignant Conditions[†]					
Pancreas	100	90	9	0	1
Chronic Heart Disease/ Hypertension	85	81	4	0	0
Gastrointestinal	147	140	7	0	0
Genitourinary	190	174	15	1	0

[†] including treated subjects

CLINICAL PERFORMANCE

Upper Reference Limit (URL)


The upper reference limit (URL) for the Access GI Monitor assay was determined using a total of 291 serum samples from apparently healthy females (150) and males (141). The 95th percentile, 35 U/mL CA 19-9 antigen, was set as the URL for the Access GI Monitor assay results for the combined female and male population. The distribution of Access GI Monitor results for this apparently healthy population is provided in the Expected Values table above.

Monitoring of Patients Diagnosed With Pancreatic Cancer


In this study, a total of 255 serum samples were obtained from 63 subjects (ages ranging from 28 to 83 years) who were diagnosed with pancreatic cancer (stages I to IV). These subjects were monitored over the course of disease, ranging from 21 days to 66 months.

Below are three examples showing serial monitoring profiles for the Access GI Monitor CA 19-9 antigen values and the clinical status.


Pancreatic Cancer Serial Monitoring Patient A



Pancreatic Cancer Serial Monitoring
Patient B



**Pancreatic Cancer Serial Monitoring
Patient C**



Based on regression models, a 20% Least Significant %Change (LS %Change) was selected to cover the imprecision across the range of Access GI Monitor concentrations. The LS %Change represents the minimum magnitude change between two serial CA 19-9 antigen measurements that could not be attributed to assay variation or noise. The LS %Change corresponds to 2.5 times the %CV (coefficient of variation) for imprecision, for the Access GI Monitor assay.

The effectiveness of CA 19-9 antigen measurements as an aid in monitoring disease status in patients diagnosed with pancreatic cancer was determined by assessing changes in CA 19-9 antigen levels in serial sets (pairs) with change in disease status. Of the 63 serial monitored subjects, ten (10) of the subjects were excluded from these evaluations as they were presumed to be CA 19-9 antigen non-expressors with CA 19-9 antigen concentrations ≤ 10 U/mL for all available serial blood draws. The remaining 53 pancreatic cancer subjects, from the serial monitoring study, were analyzed using one serial set (two sequential visits per set) per subject. In this evaluation, disease status was classified as "Progression" or "No Progression", with "No Progression" consisting of "stable", "responding", or "no evidence of disease (NED)" between two consecutive serial draws. The results from these analyses, on a per patient basis, are presented below.

Association of CA 19-9 Antigen Concentrations vs. Disease Status (Per Patient Basis)

Access GI Monitor	Change in Clinical Status		Total
Marker Change	Progression	No Progression	
20% Increase	25	11	36
No Increase	7	10	17
Total	32	21	53
Access GI Monitor	95% Confidence Interval		
Positive Concordance	78.1%	61.2%	89.0%
Negative Concordance	47.6%	28.3%	67.6%
Total Concordance	66.0%	52.6%	77.3%

The effectiveness of CA 19-9 antigen measurements as an aid in monitoring disease status in patients diagnosed with pancreatic cancer was also determined by assessing changes in CA 19-9 antigen levels in serial sets (sequential visit pairs) with changes in disease status. Samples from the 53 patients from the serial monitoring study, for a total of 168 serial sets (sequential visit pairs), were further analyzed for %change in CA 19-9 antigen concentrations across serial sets and disease status. In this evaluation disease status, between two consecutive serial draws, was classified as “Progression” or “No Progression”. The distribution of results across the three disease classifications relative to the 20% LS %Change, on a per sample basis, are presented below for the Access GI Monitor assay.

% Change in CA 19-9 Antigen Concentrations vs. Disease Status Based on 20% Least Significant % Change (Per Sample Basis)

Access GI Monitor	Change in Disease State		Total
Change in CA 19-9 Antigen	Progression	No Progression	
Significant Change > 20%	41	37	78
No Change ≤ 20%	28	62	90
Total	69	99	168
Access GI Monitor	95% Confidence Interval		
Positive Concordance	59.4%	47.7%	70.2%
Negative Concordance	62.6%	52.8%	71.5%
Total Concordance	61.3%	58.8%	68.3%

PROCEDURAL NOTES

LIMITATIONS

1. The Access GI Monitor results should be interpreted in light of the total clinical presentation of the patient, including: symptoms, clinical history, data from additional tests, and other appropriate information.
2. Serum or plasma CA 19-9 antigen concentrations should not be interpreted as absolute evidence for the presence or absence of cancer. Elevated concentrations may be observed in the serum or plasma of patients with benign conditions or other non-cancer disorders, as well as in pancreatic cancer and other malignant diseases. The Access GI Monitor assay should not be used as a cancer screening test.

3. Patients must possess the ability to express the Lewis blood group antigen or they will be unable to produce the CA 19-9 antigen even in the presence of proven malignancy. A patient with a positive genotype for the Lewis antigen may produce varying levels of CA 19-9 antigen. Phenotyping for the presence of the Lewis blood group antigen may be insufficient to detect true Lewis antigen negative individuals.
4. Samples can be accurately measured within the analytic range of the lower limit of detection and the highest calibrator value (approximately 0.8-2,000 U/mL).
 - If a sample contains less than the lower limit of detection for the assay, report the results as less than that value (i.e., < 0.8 U/mL). When the DxI system onboard dilution feature is used, the system will report results as less than 1,700 U/mL.
 - If a sample contains more than the stated value of the highest Access GI Monitor Calibrator (S5), report the result as greater than that value (i.e., > 2,000 U/mL). Alternatively, dilute one volume of sample with 9 volumes of Access Sample Diluent A. Refer to the appropriate system manuals and/or Help system for instructions on entering a sample dilution in a test request. The system reports the results adjusted for the dilution.

The DxI system onboard dilution feature automates the dilution process, using one volume of sample with nine volumes of Access Sample Diluent A, allowing samples to be quantitated up to approximately 20,000 U/mL. The system reports the results adjusted for the dilution.

5. For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the patient sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays. Additionally, other heterophile antibodies such as human anti-goat antibodies may be present in patient samples.^{12,13}

Such interfering antibodies may cause erroneous results. Carefully evaluate the results of patients suspected of having these antibodies.

6. The Access GI Monitor assay does not demonstrate any “hook” effect up to 800,000 U/mL.
7. This assay is susceptible to interference from high levels of biotin. The recommended daily intake for biotin is 30 µg. High doses of biotin (up to 30 mg per day) may be taken as a dietary supplement aimed at improving hair loss, nail growth, or skin condition.¹⁴

Some pharmacokinetic studies have shown that serum concentrations of biotin can reach up to 300 ng/mL when subjects taking supplements containing 20 mg biotin¹⁵ or 1,160 ng/mL for subjects taking doses of biotin up to 300 mg.¹⁴ These studies were performed in apparently healthy subjects and some patients may be taking supplements with biotin at levels > 20 mg per day.

Clearance rates of biotin may differ between patients tested with this device (e.g., patients with renal impairment), which may lead to higher than expected, or prolonged, concentrations in serum. If medically practicable, patients receiving biotin supplements should discontinue use prior to sample draws to minimize the risk of interference. Specimens with biotin concentrations ≤ 25 ng/mL demonstrated non-significant bias (≤ 10%) in results. Biotin concentrations > 25 ng/mL can lead to significant (> 10%) negative bias in GI Monitor results.

PERFORMANCE CHARACTERISTICS

PERFORMANCE CHARACTERISTICS

METHODS COMPARISON

A comparison of 405 values using the Access GI Monitor assay on the Access Immunoassay system and a commercially available radioimmunoassay kit gave the following statistical data using Deming calculations:

n	Range of Observations (U/mL)	Intercept (U/mL)	Slope	Correlation Coefficient (r)
405	0-236.0	2.5726	0.9569	0.9007

SAMPLE TYPE COMPARISON

A comparison of 80 matched serum and lithium heparin plasma samples using the Access GI Monitor assay on the Access Immunoassay system gave the following statistical data using Deming calculations:

n	Range of Observations (U/mL)	Intercept (U/mL)	Slope	Correlation Coefficient (r)
80	0-1650.9	-0.5002	0.9842	0.9995

DILUTION RECOVERY (LINEARITY)

Multiple dilutions of three samples containing various CA 19-9 antigen levels with Access Sample Diluent A resulted in the following data:

Sample 1	Expected Concentration (U/mL)	Determined Concentration (U/mL)	Recovery (%)
Neat	1202.7	-	100
1:2	601.3	536.3	89.2
1:4	300.7	282.7	94.0
1:8	150.3	142.2	94.6
1:16	75.2	68.4	91.0
1:32	37.6	35.6	94.7
1:64	18.8	17.3	92.0
Mean % Recovery			92.6

Sample 2	Expected Concentration (U/mL)	Determined Concentration (U/mL)	Recovery (%)
Neat	1382.1	-	100
1:2	691.1	748.2	108.3
1:4	345.5	356.6	103.2
1:8	172.8	169.8	98.3
1:16	86.4	83.7	96.9
1:32	43.2	40.7	94.2
1:64	21.6	20.7	95.8
Mean % Recovery			99.5

Sample 3	Expected Concentration (U/mL)	Determined Concentration (U/mL)	Recovery (%)
Neat	1239.1	-	100
1:2	619.6	601.5	97.1
1:4	309.8	288.3	93.1
1:8	154.9	137.2	88.6
1:16	77.4	70.5	91.1
1:32	38.7	37.8	97.7
1:64	19.4	19.6	101.0
		Mean % Recovery	94.8

IMPRECISION

This assay exhibits total imprecision of less than 10% across the assay range. One study, using commercially available human serum based control material generating a total of 20 assays, 2 replicates per assay, over 20 days provided the following data, analyzed via analysis of variance (ANOVA).^{16,17}

Sample	Grand Mean (n=40) (U/mL)	Within Run (%CV)	Between Run (%CV)	Total Imprecision (%CV)
Level 1	17.6	6.4	5.7	8.9
Level 2	110.5	2.2	2.7	3.5
Level 3	584.6	1.7	2.5	3.1
Level 4	1664.5	1.8	2.4	3.0

ANALYTICAL SPECIFICITY / INTERFERENCES

Samples containing up to 50 mg/dL hemoglobin, 60 mg/dL bilirubin, 1,000 mg/dL triglycerides (triolein) or 9 g/dL protein (human serum albumin) do not affect the concentration of CA 19-9 antigen assayed.

The following table describes the cross-reactivity of the assay with common chemotherapeutic agents and other potential interferents.

Substance	Concentration Added	Expected (U/mL)	Observed (U/mL)	Mean % Recovery
5-Fluorouracil (Adrucil)	1 mg/mL	8.4	8.3	99
Acetaminophen (Tylenol)	0.2 mg/mL	8.9	8.8	99
Acetylsalicylic acid (Aspirin)	0.5 mg/mL	9.4	8.8	94
Adriamycin (Doxorubicin - HCL)	0.1 mg/mL	8.7	8.5	98

Substance	Concentration Added	Expected (U/mL)	Observed (U/mL)	Mean % Recovery
Amethopterin Hydrate (Methotrexate)	4.5 mg/mL	9.3	9.1	98
Aminoglutethimide	0.4 mg/mL	8.6	8.6	100
Caffeine	0.1 mg/mL	8.5	8.7	102
Cisplatin - Dichloride	1 mg/mL	8.9	8.2	92
Cyclophosphamide (Cytoxan)	0.25 mg/mL	9.4	9.4	100
Cyclosporin A	2.97×10^{-6} mg/mL	9.8	9.2	94
Digoxin	5.0×10^{-6} mg/mL	9.7	9.4	97
Folinic Acid (Leucovorin)	1.1 mg/mL	9.1	9.4	103
Gentamicin-Sulphate Salt	0.12 mg/mL	9.0	9.6	107
Heparin	50 U/mL	8.3	9.0	108
Lidocaine Hydrochloride	0.06 mg/mL	8.5	8.8	104
Lithium Carbonate (Eskalith)	0.035 mg/mL	9.0	8.3	92
Mitomycin C	0.006 mg/mL	9.2	10.1	110
Novantrone (Mitoxantrone)	0.5 mg/mL	8.3	8.1	98
Paclitaxel	3.5×10^{-6} mg/mL	9.4	9.2	98
Propranolol HCl (Inderal)	5.0×10^{-6} mg/mL	9.0	8.7	97
Quinidine gluconate (Duraguin, Quinaglute)	0.05 mg/mL	9.0	8.9	99
Salicylate (Salicylic acid - Sodium Salt)	0.5 mg/mL	8.9	8.7	98
Tamoxifen - Citrate Salt	0.13 mg/mL	9.3	8.6	92
Theophylline (Aminophylline)	0.25 mg/mL	8.9	8.8	99
Tobramycin - Sulfate Salt	0.015 mg/mL	9.1	9.4	103

Biotin

The following concentrations of biotin were spiked into normal serum samples at high and low GI monitor concentrations and found to give the following percent change in result response.

Analyte Range	Analyte Concentration	Biotin (ng/mL)								
		10	25	50	75	90	100	300	600	1,200
Low	24 - 29 U/mL	0%	-1%	-11%	-15%	-16%	-18%	-30%	-36%	-42%
High	42 - 55 U/mL	-2%	-7%	-8%	-8%	-10%	-18%	-29%	-25%	-40%

ANALYTICAL SENSITIVITY

The lowest detectable level of CA 19-9 antigen distinguishable from zero (Access GI Monitor Calibrator S0) with 95% confidence is 0.8 U/mL. This value is determined by processing a complete six point calibration curve, controls, and 10 replicates of the zero calibrator in multiple assays. The analytical sensitivity value is calculated from the curve at the point that is two standard deviations from the fitted zero calibrator signal.

ADDITIONAL INFORMATION

Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

May be covered by one or more pat. -see www.beckmancoulter.com/patents.

REVISION HISTORY

Revision J

Remove CE Mark and EC REP Address, Update GHS Hazard Information, and Website Address

Revision K

Updated "Analytical Specificity/Interferences" section.

Updated "Expected Results" section.

Revision L

Updated ProClin trademark statement.

SYMBOLS KEY

Glossary of Symbols is available at beckmancoulter.com/techdocs (document number C02724).

REFERENCES

1. Lillemoe KD, Yeo CY, and Cameron JL. Pancreatic Cancer: State-of-the-Art Care. *CA Cancer J. Clin.* 2000; 50: 241-268.
2. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. *Am J Gastroenterol.* 1990; 85 (4): 350-355.
3. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric Assay for a Monoclonal Antibody-Defined Tumor Marker, CA 19-9. *Clin Chem.* 1983; 29: 549-552.
4. Steinberg WK, Gelfand R, Anderson KK, Glen J, Kurtzman SH, Sindelar WF, et. al. Comparison of the Sensitivity and Specificity of the CA 19-9 and Carcinoembryonic Antigen Assays in Detecting Cancer of the Pancreas. *Gastroenterology.* 1985; 90: 343-349.
5. Ritts RE Jr, Del Villano BC, Go VLW, Herberman RB, Klug TL, Zurawski VR Jr. Initial Clinical Evaluation of an Immunoradiometric Assay for CA 19-9 Using the NCI Serum Bank. *Int J. Cancer.* 1984; 33: 339-345.
6. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund C, Makela O. Comparison of a New Tumor Marker, CA 19-9, with Alpha-Fetoprotein and Carcinoembryonic Antigen in Patients with Upper Gastrointestinal Diseases. *J Clin Pathol.* 1984; 37: 218-222.
7. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the Utility of a Radioimmunoassay for Serum CA 19-9 Levels in Patients Before and After Treatment of Carcinoma of the Pancreas. *J Clin Oncol.* 1988; 6 (3): 462-468.
8. Willet CG, Dayl WJ, Warshaw AL. CA 19-9 is an index of response to neoadjuvantive chemoradiation therapy in pancreatic cancer. *Am J Surg.* 1996; 172: 350-352.
9. Approved Guideline - Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests, GP44-A4. 2010. Clinical and Laboratory Standards Institute.
10. HHS Publication, 5th ed., December 2009. Biosafety in Microbiological and Biomedical Laboratories.
11. Cembrowski GS, Carey RN. Laboratory quality management: QC \Rightarrow QA. ASCP Press, Chicago, IL, 1989.
12. Kricka L. Interferences in immunoassays - still a threat. *Clin Chem* 2000; 46: 1037-1038.
13. Bjerner J, et al. Immunometric assay interference: incidence and prevention. *Clin Chem* 2002; 48: 613-621.
14. Piketty ML, et al. 2017. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. *Clin Chem Lab Med.* 55(6):817-825.
15. Grimsey P, et al. 2017. Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference. 2(4):247-256.
16. Krouwer JS, Rabinowitz R. How to improve estimates of imprecision. *Clinical Chemistry*, 1984; 30: 290-292.
17. Tentative Guideline - User evaluation of precision performance of clinical chemistry devices, EP5-T. 1984. National Committee for Clinical Laboratory Standards, 4: No. 8.



Beckman Coulter, Inc., 250 S. Kraemer Blvd., Brea, CA 92821 U.S.A.
+(1) 800-854-3633
www.beckmancoulter.com